Accordingly, detailed understanding of the chromatin remodeling events that drive transcriptional changes at the binding sites of the fusion protein and their reversibility upon SS18-SSX depletion are critical toward identifying new tumor-specific therapeutic strategies. This evidence concerns the gene SS18 and neoplasm.